Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Staphylococcus

IL-20 receptor-b (IL20R2; IL20RB)

Mouse and cell culture studies suggest inhibiting IL20RB could help treat methicillin-resistant Staphylococcus aureus (MRSA) skin infections. In a mouse model for MRSA skin infection, an anti-IL20RB mAb dosed at the time of infection decreased lesion size compared with a control antibody. In primary human keratinocytes, exposure to MRSA led to greater expression of cytokines that signal via IL20RB than no MRSA exposure. Next steps could include developing small molecule IL20RB inhibitors.

SciBX 6(30); doi:10.1038/scibx.2013.796
Published online Aug. 8, 2013

Patent and licensing information unavailable

Myles, I. A. et al. Nat. Immunol.; published online June 23, 2013;
doi:10.1038/ni.2637
Contact: Sandip K. Datta, National Institute of Allergy and Infectious Diseases, Bethesda, Md.
e-mail:
dattas@niaid.nih.gov